-
Balazs A B, Chen J, Hong C M, Rao D S, Yang L, Baltimore D, 2012: Antibody-based protection against HIV infection by vectored immunoprophylaxis[J]. Nature, 481, 81-84.
-
Barbas 3rd C F, Bjorling E, Chiodi F, Dunlop N, Cababa D, Jones T M, Zebedee S L, Persson M A, Nara P L, Norrby E, 1992: Recombinant human Fab fragments neutralize human type 1 immunodeficiency virus in vitro[J]. Proc Natl Acad Sci U S A, 89, 9339-9343. doi: 10.1073/pnas.89.19.9339
-
Binley J M, Wrin T, Korber B, Zwick M B, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petr-opoulos C J, Burton D R, 2004: Comprehensive crossclade neutralization analysis of a panel of anti-human imm-unodeficiency virus type 1 monoclonal antibodies[J]. J Virol, 78, 13232-13252. doi: 10.1128/JVI.78.23.13232-13252.2004
-
Burton D R, Barbas 3rd C F, Persson M A, Koenig S, Chanock R M, Lerner R A, 1991: A large array of human monoclonal an-tibodies to type 1 human immunodeficiency virus from com-binatorial libraries of asymptomatic seropositive individuals[J]. Proc Natl Acad Sci U S A, 88, 10134-10137. doi: 10.1073/pnas.88.22.10134
-
Burton D R, Pyati J, Koduri R, Sharp S J, Thornton G B, Parren P W, Sawyer L S, Hendry R M, Dunlop N, Nara P L, 1994: Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody[J]. Science, 266, 1024-1027. doi: 10.1126/science.7973652
-
Butler D M, Pacold M E, Jordan P S, Richman D D, Smith D M, 2009: The efficiency of single genome amplification and sequencing is improved by quantitation and use of a bio-informatics tool[J]. J Virol Methods, 162, 280-283. doi: 10.1016/j.jviromet.2009.08.002
-
Chong H, Hong K, Zhang C, Nie J, Song A, Kong W, Wang Y, 2008: Genetic and neutralization properties of HIV-1 env clones from subtype B/BC/AE infections in China[J]. J Acquir Immune Defic Syndr, 47, 535-543. doi: 10.1097/QAI.0b013e3181663967
-
Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton R E, Hill C M, Davis C B, Peiper S C, Schall T J, Littman D R, Landau N R, 1996: Identification of a major co-receptor for primary isolates of HIV-1[J]. Nature, 381, 661-666. doi: 10.1038/381661a0
-
Derdeyn C A, Decker J M, Sfakianos J N, Wu X, O’Brien W A, Ratner L, Kappes J C, Shaw G M, Hunter E, 2000: Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120[J]. J Virol, 74, 8358-8367. doi: 10.1128/JVI.74.18.8358-8367.2000
-
Duenas-Decamp M J, Peters P, Burton D, Clapham P R, 2008: Natural resistance of human immunodeficiency virus type 1 to the CD4bs antibody b12 conferred by a glycan and an arginine residue close to the CD4 binding loop[J]. J Virol, 82, 5807-5814. doi: 10.1128/JVI.02585-07
-
Gnanakaran S, Daniels M G, Bhattacharya T, Lapedes A S, Sethi A, Li M, Tang H, Greene K, Gao H, Haynes B F, Cohen M S, Shaw G M, Seaman M S, Kumar A, Gao F, Montefiori D C, Korber B, 2010: Genetic signatures in the envelope gly-coproteins of HIV-1 that associate with broadly neutralizing antibodies[J]. PLoS Comput Biol, 6, e1000955-. doi: 10.1371/journal.pcbi.1000955
-
Haynes B F, Gilbert P B, McElrath M J, Zolla-Pazner S, Tomaras G D, Alam S M, Evans D T, Montefiori D C, Karnasuta C, Sutthent R, Liao H X, DeVico A L, Lewis G K, Williams C, Pinter A, Fong Y, Janes H, DeCamp A, Huang Y, Rao M, Billings E, Karasavvas N, Robb M L, Ngauy V, de Souza M S, Paris R, Ferrari G, Bailer R T, Soderberg K A, Andrews C, Berman P W, Frahm N, De Rosa S C, Alpert M D, Yates N L, Shen X, Koup R A, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael N L, Kim J H, 2012: Immune-correlates analysis of an HIV-1 vaccine efficacy trial[J]. N Engl J Med, 366, 1275-1286. doi: 10.1056/NEJMoa1113425
-
Hessell A J, Poignard P, Hunter M, Hangartner L, Tehrani D M, Bleeker W K, Parren P W, Marx P A, Burton D R, 2009: Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques[J]. Nat Med, 15, 951-954. doi: 10.1038/nm.1974
-
Kent S J, Cooper D A, Chhi Vun M, Shao Y, Zhang L, Ganguly N, Bela B, Tamashiro H, Ditangco R, Rerks-Ngarm S, Pitisuttithum P, Van Kinh N, Bernstein A, Osmanov S, 2010: AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines[J]. PLoS Med, 7, e1000331-. doi: 10.1371/journal.pmed.1000331
-
Li Y, Migueles S A, Welcher B, Svehla K, Phogat A, Louder M K, Wu X, Shaw G M, Connors M, Wyatt R T, Mascola J R, 2007: Broad HIV-1 neutralization mediated by CD4-binding site antibodies[J]. Nat Med, 123, 1032-1034.
-
Mo H, Stamatatos L, Ip J E, Barbas C F, Parren P W, Burton D R, Moore J P, Ho D D, 1997: Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off[J]. J Virol, 71, 6869-6874.
-
Moore J P, Cao Y, Leu J, Qin L, Korber B, Ho D D, 1996: Inter and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes[J]. J Virol, 70, 427-444.
-
Nie J, Zhang C, Liu W, Wu X, Li F, Wang S, Liang F, Song A, Wang Y, 2010: Genotypic and phenotypic characterization of HIV-1 CRF01_AE env molecular clones from infections in China[J]. J Acquir Immune Defic Syndr, 53, 440-450. doi: 10.1097/QAI.0b013e3181cb8300
-
Palmer S, Kearney M, Maldarelli F, Halvas E K, Bixby C J, Bazmi H, Rock D, Falloon J, Davey Jr R T, Dewar R L, Metcalf J A, Hammer S, Mellors J W, Coffin J M, 2005: Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis[J]. J Clin Microbiol, 43, 406-413. doi: 10.1128/JCM.43.1.406-413.2005
-
Pantophlet R, Ollmann Saphire E, Poignard P, Parren P W, Wilson I A, Burton D R, 2003: Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120[J]. J Virol, 77, 642-658. doi: 10.1128/JVI.77.1.642-658.2003
-
Platt E J, Wehrly K, Kuhmann S E, Chesebro B, Kabat D, 1998: Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human imm-unodeficiency virus type 1[J]. J Virol, 72, 2855-2864.
-
Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil J G, Francis D P, Stablein D, Birx D L, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb M L, Michael N L, Kunasol P, Kim J H, Investigators M-T, 2009: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand[J]. N Engl J Med, 361, 2209-2220. doi: 10.1056/NEJMoa0908492
-
Roben P, Moore J P, Thali M, Sodroski J, Barbas 3rd C F, Bu-rton D R, 1994: Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human im-munodeficiency virus type 1[J]. J Virol, 68, 4821-4828.
-
Rolland M, Edlefsen P T, Larsen B B, Tovanabutra S, Sanders-Buell E, Hertz T, deCamp A C, Carrico C, Menis S, Magaret C A, Ahmed H, Juraska M, Chen L, Konopa P, Nariya S, Stoddard J N, Wong K, Zhao H, Deng W, Maust B S, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell R J, deSouza M S, Nitayaphan S, Rerks-Ngarm S, Robb M L, McLellan J S, Georgiev I, Kwong P D, Carlson J M, Michael N L, Schief W R, Gilbert P B, Mullins J I, Kim J H, 2012: Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2[J]. Nature, 490, 417-420. doi: 10.1038/nature11519
-
Saphire E O, Parren P W, Pantophlet R, Zwick M B, Morris G M, Rudd P M, Dwek R A, Stanfield R L, Burton D R, Wilson I A, 2001: Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design[J]. Science, 293, 1155-1159. doi: 10.1126/science.1061692
-
Shang H, Han X, Shi X, Zuo T, Goldin M, Chen D, Han B, Sun W, Wu H, Wang X, Zhang L, 2011: Genetic and neutralization sen-sitivity of diverse HIV-1 env clones from chronically in-fected patients in China[J]. J Biol Chem, 286, 14531-14541. doi: 10.1074/jbc.M111.224527
-
Teng T, Shao Y, 2011: Scientific approaches to AIDS pre-vention and control in China[J]. Adv Dent Res, 23, 10-12. doi: 10.1177/0022034511398871
-
Utachee P, Isarangkura-na-ayuthaya P, Tokunaga K, Ikuta K, Takeda N, Kameoka M, 2014: Impact of amino acid substitutions in the V2 and C2 regions of human im-munodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 on viral neutralization susceptibility to broadly neutralizing antibodies specific for the CD4 binding site[J]. Retrovirology, 11, 32-. doi: 10.1186/1742-4690-11-32
-
Utachee P, Nakamura S, Isarangkura-na-ayuthaya P, Tokunaga K, Sawanpanyalert P, Ikuta K, Auwanit W, Kameoka M, 2010: Two N-linked glycosylation sites in the V2 and C2 regions of human immunodeficiency virus type 1 CRF01_AE envelope glycoprotein gp120 regulate viral neutralization susceptibility to the human monoclonal antibody specific for the CD4 binding domain[J]. J Virol, 84, 4311-4320. doi: 10.1128/JVI.02619-09
-
Veselinovic M, Neff C P, Mulder L R, Akkina R, 2012: Topical gel formulation of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 confers protection against HIV-1 vaginal challenge in a humanized mouse model[J]. Virology, 432, 505-510. doi: 10.1016/j.virol.2012.06.025
-
Walker L M, Phogat S K, Chan-Hui P Y, Wagner D, Phung P, Goss J L, Wrin T, Simek M D, Fling S, Mitcham J L, Lehrman J K, Priddy F H, Olsen O A, Frey S M, Hammond P W, Kaminsky S, Zamb T, Moyle M, Koff W C, Poignard P, Burton D R, 2009: Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target[J]. Science, 326, 285-289. doi: 10.1126/science.1178746
-
Walker L M, Huber M, Doores K J, Falkowska E, Pejchal R, Julien J P, Wang S K, Ramos A, Chan-Hui P Y, Moyle M, Mitcham J L, Hammond P W, Olsen O A, Phung P, Fling S, Wong C H, Phogat S, Wrin T, Simek M D, Koff W C, Wilson I A, Burton D R, Poignard P, 2011: Broad neutralization coverage of HIV by multiple highly potent antibodies[J]. Nature, 477, 466-470. doi: 10.1038/nature10373
-
Wang S, Nie J, Wang Y, 2011: Comparisons of the genetic and neutralization properties of HIV-1 subtype C and CRF07/08_BC env molecular clones isolated from infections in China[J]. Virus Res, 155, 137-146. doi: 10.1016/j.virusres.2010.09.012
-
Wang Y, Li X, Song A, Zhang C, Chen Y, Chen C, Lin Y, Shun L, Li L, Liu Y, Yang J, Yang B, Tang Q, Harrison T J, 2005: Prevalence and partial sequence analysis of human T cell lymphotropic virus type I in China[J]. J Med Virol, 76, 613-618. doi: 10.1002/jmv.20405
-
Wei X, Decker J M, Liu H, Zhang Z, Arani R B, Kilby J M, Saag M S, Wu X, Shaw G M, Kappes J C, 2002: Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy[J]. Antimicrob Agents Chemother, 46, 1896-1905. doi: 10.1128/AAC.46.6.1896-1905.2002
-
Wei X, Decker J M, Wang S, Hui H, Kappes J C, Wu X, Salazar-Gonzalez J F, Salazar M G, Kilby J M, Saag M S, Komarova N L, Nowak M A, Hahn B H, Kwong P D, Shaw G M, 2003: Antibody neutralization and escape by HIV-1[J]. Nature, 422, 307-312. doi: 10.1038/nature01470
-
Wu X, Yang Z Y, Li Y, Hogerkorp C M, Schief W R, Seaman M S, Zhou T, Schmidt S D, Wu L, Xu L, Longo N S, McKee K, O'Dell S, Louder M K, Wycuff D L, Feng Y, Nason M, Doria-Rose N, Connors M, Kwong P D, Roederer M, Wyatt R T, Nabel G J, Mascola J R, 2010: Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1[J]. Science, 329, 856-861. doi: 10.1126/science.1187659
-
Wyatt R, Sodroski J, 1998: The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens[J]. Science, 280, 1884-1888. doi: 10.1126/science.280.5371.1884
-
Zhang L, Chen Z, Cao Y, Yu J, Li G, Yu W, Yin N, Mei S, Li L, Balfe P, He T, Ba L, Zhang F, Lin H H, Yuen M F, Lai C L, Ho D D, 2004: Molecular characterization of human immunodeficiency virus type 1 and hepatitis C virus in paid blood donors and injection drug users in china[J]. J Virol, 78, 13591-13599. doi: 10.1128/JVI.78.24.13591-13599.2004
-
Zhang Y, Lu L, Ba L, Liu L, Yang L, Jia M, Wang H, Fang Q, Shi Y, Yan W, Chang G, Zhang L, Ho D D, Chen Z, 2006: Dominance of HIV-1 subtype CRF01_AE in sexually acquired cases leads to a new epidemic in Yunnan province of China[J]. PLoS Med, 3, e443-. doi: 10.1371/journal.pmed.0030443
-
Zolla-Pazner S, deCamp A C, Cardozo T, Karasavvas N, Gottardo R, Williams C, Morris D E, Tomaras G, Rao M, Billings E, Berman P, Shen X, Andrews C, O'Connell R J, Ngauy V, Nitayaphan S, de Souza M, Korber B, Koup R, Bailer R T, Mascola J R, Pinter A, Montefiori D, Haynes B F, Robb M L, Rerks-Ngarm S, Michael N L, Gilbert P B, Kim J H, 2013: Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial[J]. PLoS One, 8, e53629-. doi: 10.1371/journal.pone.0053629